Northern Capital Management LLC acquired a new position in shares of Gilead Sciences Inc. (NASDAQ:GILD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 6,545 shares of the biopharmaceutical company’s stock, valued at approximately $546,000.
Several other large investors have also made changes to their positions in the stock. Bank of Montreal Can acquired a new stake in shares of Gilead Sciences during the second quarter worth about $427,750,000. Investec Asset Management LTD acquired a new stake in shares of Gilead Sciences during the first quarter worth about $280,342,000. NN Investment Partners Holdings N.V. acquired a new stake in shares of Gilead Sciences during the first quarter worth about $180,268,000. Temasek Holdings Private Ltd boosted its stake in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. Finally, Old Mutual Global Investors UK Ltd. boosted its stake in shares of Gilead Sciences by 256.3% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,156,623 shares of the biopharmaceutical company’s stock worth $96,485,000 after buying an additional 832,028 shares during the period. 77.93% of the stock is owned by institutional investors.
Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.42% on Friday, hitting $72.75. 7,359,055 shares of the company were exchanged. The stock has a market capitalization of $96.01 billion, a P/E ratio of 6.38 and a beta of 1.10. The stock’s 50-day moving average price is $77.93 and its 200-day moving average price is $84.45. Gilead Sciences Inc. has a 52-week low of $72.21 and a 52-week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the prior year, the firm posted $3.15 EPS. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.58%. Gilead Sciences’s dividend payout ratio is presently 16.56%.
A number of equities research analysts recently commented on the stock. Barclays PLC reiterated an “overweight” rating on shares of Gilead Sciences in a report on Thursday, July 28th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Monday, October 3rd. Bank of America Corp. reiterated a “neutral” rating and set a $100.00 price target on shares of Gilead Sciences in a report on Sunday, September 25th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Finally, Leerink Swann set a $112.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, September 22nd. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $103.78.
In other Gilead Sciences news, insider John F. Milligan sold 70,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total value of $5,441,800.00. Following the sale, the insider now owns 1,128,963 shares in the company, valued at approximately $87,765,583.62. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the sale, the insider now owns 4,119,727 shares in the company, valued at approximately $331,638,023.50. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.